Catalio Capital Management

Biotech company developing AI-powered multiomics blood tests for early cancer detection. Its platform analyzes cell-free DNA, methylation patterns, and protein biomarkers from routine blood draws to screen for cancers in their earliest stages. Lead product SimpleScreen targets FDA approval for colorectal cancer screening.

Cartography Biosciences is a precision oncology company developing cancer immunotherapies guided by the first comprehensive antigen atlas for immuno-oncology targets. The company's proprietary ATLAS and SUMMIT platforms combine single-cell genomics, proteomics, and computational biology to identify tumor-selective antigens, enabling antibody-based therapies that target tumors more precisely than existing therapeutics.